logo-loader
HealthPharma & Biotech
Neurotrope

Neurotrope welcomes industry veteran to board

Neurotrope, which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.

BigBoardRoom_56c724e3788fc.jpg
Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity...

Neurotrope (OTCMKTS: NTRP), which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.

Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity.  

"We are very pleased to welcome Susanne to our board," said Charles S. Ramat, President and CEO of Neurotrope.

"She is an industry veteran with a tremendous scientific background including a dual Ph.D. in Chemistry and Biochemistry and extensive understanding of various therapeutic areas.

"Susanne’s proven experience in scientific operations, strategic planning and managing the growth of emerging companies will prove invaluable as we advance Bryostatin-1 through our Phase 2b proof-of-concept trial in moderately-severe to severe Alzheimer’s disease.”

Wilke is the Co-founder and CEO of CrossBridge International, an advisory specializing in integrating proprietary scientific developments with sophisticated marketing and financing plans for biotech companies.

Dr. Wilke also served as Director of the Life Sciences group at Wombat Capital Markets SAS, a financial advisory firm specializing in cross-border transactions between the U.S. and Europe.

Neurotrope has successfully completed a Phase 2a trial, in which all primary endpoints were met, and is currently dosing patients in a Phase 2b proof-of-concept trial.

Quick facts: Neurotrope

Price: $0.88

Market: NASDAQ
Market Cap: $11.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: KRM22 PLC reports growing pipeline of new opportunities

KRM22 PLC's (LON:KRM) Keith Todd speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019. The risk management software firm, which floated in April last year, says its pipeline of new opportunities has increased over the period, but some...

1 hour, 42 minutes ago

2 min read